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Abstract
The HIV-1 accessory protein Nef enhances virus infectivity by facilitating an early post-entry step of infection. Nef acts in the virus producer
cell, leading to a beneficial modification to HIV-1 particles. Nef itself is incorporated into HIV-1 particles, where it is cleaved by the viral protease
during virion maturation. To probe the role of virion-associated Nef in HIV-1 infection, we generated a fusion protein consisting of the host protein
cyclophilin A (CypA) linked to the amino terminus of Nef. The resulting CypA-Nef protein enhanced the infectivity of Nef-defective HIV-1
particles and was specifically incorporated into the virions via association with Gag during particle assembly. Pharmacologic or genetic inhibition
of CypA-Nef binding to Gag prevented incorporation of CypA-Nef into virions and inhibited infectivity enhancement. Our results indicate that
infectivity enhancement by Nef requires its association with a component of the assembling HIV-1 particle.
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Human immunodeficiency virus type 1 (HIV-1) and other
lentiviruses encode accessory proteins in addition to the proto-
typic gag, pol and env open reading frames. One of these, Nef,
is found only in primate lentiviruses and is required for efficient
HIV-1 replication in primary CD4+ T cells, macrophages, and
some T cell lines (Miller et al., 1994; Spina et al., 1994).
Inactivation of Nef in HIV-1 and the related simian immuno-
deficiency virus (SIV) leads to attenuated replication and de-
layed onset of disease in the infected host (Kestler et al., 1991;
Learmont et al., 1999). Expression of Nef also has profound
effects on cells, including downmodulation of cell surface CD4
and MHC class I expression as well as enhancement of T cell
activation (Baur et al., 1994; Garcia and Miller, 1991; Kestler
et al., 1991; Schwartz et al., 1996).
Nef-defective viral particles are 4-40 fold less infectious than
wild type HIV-1 in single cycle infection assays (Aiken and
Trono, 1995; Chowers et al., 1994; Miller et al., 1994). Despite⁎ Corresponding author. Fax: +1 615 343 7392.
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hances HIV-1 infectivity remains unclear. Nef does not markedly
enhance the efficiency of HIV-1 entry into cells, nor does it
appear to modulate the intrinsic stability of the HIV-1 capsid
shell that surrounds the viral ribonucleoprotein complex (Cav-
rois et al., 2004; Day et al., 2004; Forshey and Aiken, 2003;
Tobiume et al., 2003). Nef-defective HIV-1 particles contain
normal quantities of reverse transcriptase and enter cells effi-
ciently but are impaired for reverse transcription in target cells
(Aiken and Trono, 1995; Chowers et al., 1995; Schwartz et al.,
1995). Wild type and Nef-defective virions exhibit similar pro-
tein compositions (Miller et al., 1995; Schwartz et al., 1995),
except when produced in cells expressing CD4, where Nef-
induced CD4 down regulation promotes incorporation of the
viral envelope glycoproteins into HIV-1 particles (Lama et al.,
1999; Lundquist et al., 2004; Ross et al., 1999). Expression of
Nef in trans in the virus-producing cell, but not in the target cell,
complements the impaired infectivity of Nef-defective HIV-1
particles (Aiken and Trono, 1995; Miller et al., 1995). A recent
study showed that the host protein dynamin 2 is required for
HIV-1 infectivity enhancement by Nef (Pizzato et al., 2007), and
Nef has been reported to promote incorporation of cholesterol
Fig. 1. Protein constructs used in this study and their expression in 293T cells.
(A) Schematic of the five proteins used in this study. (B) Expression of the
proteins in 293T cells. Cell lysates were analyzed by immunoblotting. Proteins
in the left panel were detected with rabbit antibody for Nef, and proteins in the
right panel were detected with rat antibody for HA tag. Abbreviations are as
follows: C, control vector; WT, wild type HIV-1; CypA, cyclophilin A; HA:
hemagglutinin epitope tag; CA, viral capsid protein.
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between wild type and Nef-defective virions is the presence of
Nef itself in HIV-1 particles (Bukovsky et al., 1997; Pandori
et al., 1996; Welker et al., 1996), where it is cleaved by the viral
protease. Collectively, these observations suggest that Nef may
promote HIV-1 infection by modulating the budding virion to
facilitate uncoating, intracellular transport, or reverse transcrip-
tion in target cells.
Incorporation of Nef into HIV-1 particles has been correlated
with infectivity enhancement. Incorporation of Nef into HIV-1
particles depends on its association with cell membranes: muta-
tions that prevent its myristoylation, as well as those in its amino
terminal basic domain, result in impaired virion incorporation as
well as reduced HIV-1 infectivity (Aiken and Trono, 1995;
Welker et al., 1998). Mutations in a C-terminal region of Nef
were also found to inhibit virion incorporation of Nef and HIV-1
infectivity (Zheng et al., 2003). However, a limitation of genetic
loss-of-function studies is the possibility of pleiotropic effects
of the mutations; such studies must therefore be interpreted with
caution. Thus, a genetic correlation of infectivity enhancement
with the presence of Nef in HIV-1 particles does not necessarily
establish a role of virion-associated Nef in HIV-1 infection.
The host cell protein cyclophilin A (CypA) also promotes
HIV-1 infection. CypA is a peptidylprolyl isomerase and the
target of the immunosuppressive drug cyclosporine A (CsA).
CsA inhibits HIV-1 replication in primary Tcells and established
T cell lines (Bartz et al., 1995; Karpas et al., 1992; Wainberg
et al., 1988). CypA is incorporated into HIV-1 particles via
association with the CA region of Gag (Franke et al., 1994; Thali
et al., 1994a). Mutations in Gag that inhibit CypA binding also
reduce HIV-1 infectivity, as does production of HIV-1 particles
in the presence of CsA (Braaten et al., 1996; Franke et al., 1994;
Thali et al., 1994a). These findings suggested that incorporation
of CypA into HIV-1 particles is necessary of optimal infectivity.
However, recent studies using CypA-deficient cells have shown
that the decrease in HIV-1 infectivity observed when virions are
produced in the presence of CsA is independent of the CypA–
Gag interaction (Hatziioannou et al., 2005; Sokolskaja et al.,
2004). Thus, it appears that the engagement of the viral capsid
by target cell CypA following HIV-1 entry promotes HIV-1
infection.
In the present study, we exploited the ability of CypA to be
specifically incorporated into HIV-1 particles to examine the
role of producer cell Nef in HIV-1 infectivity. By analyzing the
effects of an engineered CypA–Nef fusion protein, we obtained
novel evidence that association of Nef with the assembling
virion is necessary for enhancement of HIV-1 infectivity by the
viral protein.
Results
Expression of a CypA–Nef fusion protein
To regulate incorporation of Nef into HIV-1 particles, we
constructed a cDNA encoding a fusion protein consisting of
CypA fused to the amino terminus of HIV-1 Nef (Fig. 1A).
Because Nef is myristylated at its amino terminus and thismodification is required for incorporation into HIV-1 particles
during their assembly, we expected that virion incorporation of
the resulting CypA–Nef fusion protein (CypA–Nef) would
require interaction of the CypA region of the molecule with Gag
during assembly. Both Nef and CypA–Nef were efficiently
expressed in transfected 293T cells, as detected by immuno-
blotting using a Nef-specific antiserum (Fig. 1B). As a control
for CypA–Nef, we also generated CypA expression plasmid. To
circumvent the interfering immunoblotting signal from the
endogenous CypA, HA-tagged CypA and HA-tagged CypA–
Nef were also constructed. These proteins were expressed under
control of the CMV promoter and were produced at similar
levels (Fig. 1B). Immunoblot analysis of endogenous CypA and
β-actin levels demonstrated that overexpression of Nef, CypA–
Nef, HA–CypA, or HA–CypA–Nef did not significantly alter
the endogenous level of CypA in 293T cells (data not shown).
CypA–Nef enhances the infectivity of Nef-defective HIV-1
TodeterminewhetherCypA–Nef can functionally complement
the reduced infectivity of Nef-defective particles, we cotransfected
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encoding CypA–Nef or Nef and analyzed the infectivity of the
resulting virus stocks by titration on P4 reporter cells. The P4 cell
line is a HeLa cell derivative that has been modified to express
human CD4 and contains a stably-transfected Tat-responsive
lacZ reporter. Infection of these cells with HIV results in ex-
pression of Tat and expression of β-galactosidase, thus allowing
quantitation of infected cells following visualization by staining
with X-gal. The infectivity of Nef-defective HIV-1 particles was
enhanced by CypA–Nef by approximately three-fold, to a level
approximately one-half that of wild type HIV-1 but similar to the
infectivity of Nef-defective HIV-1 particles complemented by a
Nef-expression plasmid (Fig. 2A). To determine whether the Nef
portion of CypA–Nef is necessary for infectivity enhancement,
we produced Nef-defective HIV-1 particles by cotransfection of
293T cells with a vector encoding only CypA. The results indi-
cated that exogenous CypA alone did not enhance the infectivity
of Nef-defective virions (Fig. 2B). Viruses were also produced by
cotransfection of Nef-defective HIV-1 provirus with plasmids
encoding the HA-tagged proteins. The resulting viruses were
then assayed for infectivity. HA–CypA–Nef enhanced the
infectivity of Nef-defective HIV-1 while HA–CypA did not
(Fig. 2B). Together, these data suggest that CypA–Nef enhances
infectivity by a mechanism that depends on the Nef portion of the
fusion protein. Therefore, the strategy could be useful for testingFig. 2. CypA–Nef is incorporated into Nef-defective HIV-1 particles and enhances th
defective HIV-1 provirus together with plasmids encoding the indicated proteins. Wild
assayed for p24 and titrated on P4 indicator target cells. Infectivity was determined as
are the relative infectivity values obtained from 3 independent experiments, with erro
that of the control Nef-defective virus. (B) The infectivity results from a representative
of each virus. (C) Wild type and Nef-defective virions were produced by cotransfecti
assayed for infectivity on P4 indicator cells. Infectivity is shown relative to the corre
effects of expression of Nef and CypA-Nef on the two viruses. (D) Immunoblot analy
shown in this figure are representative of 2 independent experiments.the requirement for association of Nef with the assembling virion
in HIV-1 infectivity enhancement.
To examine whether CypA–Nef functionally substitutes for
Nef in HIV-1 infection, we asked whether this fusion protein
could also enhance the infectivity of wild type HIV-1 particles.
To test this, cells were cotransfected with wild type and Nef-
defective HIV-1 proviruses together with Nef or CypA–Nef
expression vectors, and the resulting virus stocks were assayed
for infectivity. CypA–Nef and Nef enhanced the infectivity of
wild type HIV-1 only slightly, while both Nef and CypA–Nef
enhanced the infectivity of Nef-defective HIV-1 by three-fold
(Fig. 2C). These results indicate that CypA–Nef expression
during HIV-1 particle production specifically complements the
infectivity impairment resulting from the lack of Nef.
CypA–Nef is incorporated into the virion and associates with
the viral core
To test whether CypA–Nef is incorporated into HIV-1 parti-
cles, we purified the virions from the culture supernatants and
prepared lysates of the transfected 293Tcells. Analysis of protein
immunoblots revealed the presence of Nef and CypA–Nef in
viral particles (Fig. 2D). Two major bands were observed in the
particles containing CypA–Nef, corresponding in size to the full-
length fusion protein and a product equivalent in mobility witheir infectivity. Viruses were produced in 293T cells by cotransfection with a Nef-
type (WT) HIV-1 was tested as a control. Virus supernatants were harvested and
the number of infected cells per ng of p24 in the respective inocula. (A) Shown
r bars representing one standard deviation. Infectivity values were normalized to
single experiment. Error bars represent the standard deviation of triplicate assays
on with constructs encoding Nef or CypA-Nef. The resulting supernatants were
sponding Nef-defective and wild type control viruses to illustrate the differential
sis of pelleted virus particles with antibodies specific for Nef and CA. The results
Fig. 3. CypA-Nef copurifies with HIV-1 cores. Concentrated HIV-1 particles
were sedimented through a layer containing 0.5% Triton X-100 into a linear
sucrose density gradient. (A) Fractions were collected from the top and p24
levels were quantified by ELISA. Top panel: Nef-defective HIV-1; bottom
panel: Nef-defective HIV-1 produced by cotransfection with the CypA–Nef
expression construct. (B) Immunoblot analysis of purified HIV-1 cores. Cores
present in the peak fraction (fraction 8) from each gradient were pelleted and
analyzed by immunoblotting using antibodies specific for Nef and CA. Lane 1:
Nef-defective HIV-1 cores; lane 2: cores isolated from Nef-defective HIV-1
particles produced in cells expressing wild type Nef; lane 3: cores isolated from
Nef-defective HIV-1 particles produced in cells expressing CypA-Nef; lane 4:
wild type HIV-1 cores. The upper and lower panels show the proteins detected
with antibodies to Nef and CA, respectively.
290 M. Qi, C. Aiken / Virology 373 (2008) 287–297the large fragment of Nef resulting from cleavage of Nef by the
viral protease. Thus both cleaved and uncleaved forms of CypA–
Nef were detected in HIV-1 particles, consistent with the known
ability of virion-associated Nef to be cleaved by the viral pro-
tease (Bukovsky et al., 1997; Pandori et al., 1996; Welker et al.,
1996). We have not yet determined whether cleavage of CypA–
Nef is mediated by the viral protease or is cleaved at the same
position as Nef itself. In some experiments, the level of virion-
associated CypA–Nef was significantly greater than that of Nef
when provided in trans by cotransfection, suggesting that the
fusion protein may be more efficiently incorporated into HIV-1
particles than Nef itself. We conclude that CypA–Nef is effi-
ciently incorporated into HIV-1 particles.
In previous studies, our laboratory reported that Nef, though
associated with the HIV-1 core, does not modulate the intrinsic
stability of the viral core (Forshey and Aiken, 2003; Kotov
et al., 1999). To determine whether CypA–Nef had an effect on
the yield of cores, which is a measure of their intrinsic stability
(Forshey et al., 2002), we purified viral cores from Nef-defec-
tive HIV-1 particles produced by cotransfection with Nef or
CypA–Nef expression constructs. The CA protein was detected
at similar levels in association with cores recovered from the
two viruses (Fig. 3A), suggesting that CypA–Nef does not alter
the intrinsic stability of the HIV-1 core. Samples of purified
cores were then analyzed by immunoblotting for the presence
of Nef and CypA–Nef. Both proteins were detected in the
purified cores at comparable levels, suggesting that CypA–Nef,
like Nef, associates with the mature HIV-1 core (Fig. 3B). This
intravirion association is likely dependent on the Nef region of
CypA–Nef, since both full-length CypA–Nef and the cleaved
fragment of Nef were copurified with the core structures, and
the bulk of virion-associated CypA is removed upon purifica-
tion of HIV-1 cores ((Welker et al., 2000); our unpublished
observations).
Genetic correlation of Nef and CypA–Nef function in HIV-1
infectivity enhancement
Point mutations in Nef have been shown to impair HIV-1
infectivity enhancement (Craig et al., 1998; Fackler et al., 2006;
Goldsmith et al., 1995; Lundquist et al., 2002). To further probe
the issue of whether CypA–Nef enhances the infectivity of Nef-
defective HIV-1 particle by a Nef-related mechanism, we con-
structed four CypA–Nef mutants encoding specific substitu-
tions in the Nef portion of the protein. Nef.4E-4Q and Nef.
EKH40AAAwere competent for enhancement of HIV-1 infecti-
vity, while HIV-1 encoding Nef.69A/72A and Nef.KEK96AAA
were poorly infectious (Fig. 4A). When we cotransfected
CypA–Nef plasmids that contain the same mutations together
with Nef-defective provirus, we observed that the mutant pro-
teins enhanced the infectivity of Nef-defective virions differ-
ently. CypA–Nef.4E-4Q and CypA–Nef.EKH40 enhanced the
infectivity of Nef-defective virions by 2.5-fold, while CypA–
Nef.69A/72A and CypA–Nef.KEK96AAA failed to enhance
the infectivity of Nef-defective virions (Fig. 4B). We observed a
statistically significant correlation of the infectivity enhance-
ment by CypA–Nef mutants in trans and Nef mutants in cis(R2 =0.9991; pb0.05 by Spearman's rank correlation test;
Fig. 4C). Immunoblot analysis confirmed that the mutant
CypA–Nef proteins were efficiently incorporated into HIV-1
Fig. 4. Point mutations in the Nef portion of CypA-Nef abolish infectivity enhancement. Viral supernatants were harvested and assayed for infectivity on P4 cells. The
results shown are representative of 3 independent experiments. (A) Infectivity of HIV-1 mutants encoding substitutions in nef. (B) Infectivity of virions generated by
cotransfection of the CypA-Nef mutants and nef-defective provirus. (C) Plot of infectivity of Nef mutant viruses (abscissa) vs. viruses complemented with the
corresponding mutant CypA–Nef proteins (ordinate). (D) Immunoblot analysis of CypA–Nef expression in 293T cells (upper panel) and incorporation into Nef-
defective HIV-1 particles (lower panel).
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Nef employ a common mechanism to enhance the infectivity of
Nef-defective virions.
CsA treatment inhibits virion incorporation of CypA–Nef and
infectivity enhancement
To determine whether enhancement of HIV-1 infectivity by
CypA–Nef requires its association with Gag in the virus-pro-
ducing cell, we produced viruses by culturing the transfected
293T cells in the presence and absence of CsA to inhibit the
binding of CypA to Gag. This approach has been used pre-
viously to prevent the incorporation of endogenous CypA into
HIV-1 particles. Viruses were harvested and assayed for infec-tivity and assayed by immunoblotting for levels of CypA–Nef.
CsA treatment reduced the infectivity of control Nef-defective
virions by approximately three-fold (Fig. 5A), consistent with
the well documented ability of CsA to inhibit HIV-1 infectivity
when present at the time of virus production (Aiken, 1997;
Braaten et al., 1996; Steinkasserer et al., 1995; Thali et al.,
1994b). By contrast, CsA reduced the infectivity of the virions
produced by cotransfection of CypA–Nef by about 9-fold,
effectively abolishing the positive effect of CypA–Nef on HIV-1
infectivity (Fig. 5A). As a control, we also tested the effects of
CsA on Nef-defective virions produced by coexpression of Nef.
CsA inhibited the infectivity of this virus by 5-fold (Fig. 5A),
consistent with the reported greater sensitivity of wild type vs.
Nef-defectiveHIV-1 to CsA (Aiken, 1998). Immunoblot analysis
Fig. 5. CsA inhibits HIV-1 incorporation of CypA–Nef and its ability to enhance
viral infectivity. Viruses were produced in transfected cells cultured in the
presence and absence of 5 μM CsA. (A) Infectivity of viruses on P4 indicator
cells. Inset: fold inhibition of infectivity by CsA. Shown are the mean values of
triplicate infections; results are representative of two independent experiments.
(B) Immunoblot analysis of cell lysates and pelleted viruses using antibodies
specific for Nef and CA.
Fig. 6. Mutations in the CypA-binding site in Gag inhibit HIV-1 incorporation of
CypA–Nef and infectivity enhancement. Viruses were produced by cotransfec-
tion of Nef-defective proviruses containing the indicated mutations in Gag with
plasmids encoding Nef or CypA–Nef. (A) Infectivity of the viruses. Inset: ratio
of infectivity of viruses produced with and without coexpression of CypA–Nef.
(B) Immunoblot analysis of cell lysates and pelleted viruses using antibodies
specific for Nef and CA.
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virion-associated CypA–Nef but not Nef itself (Fig. 5B).
Analysis of cell lysates indicated that CsA treatment did not
significantly alter the expression of CypA–Nef or Nef (Fig. 5B).
Thus, treatment of virus-producer cells inhibited HIV-1 infec-
tivity enhancement by CypA–Nef and its incorporation of the
protein into virions. Collectively, these results suggest that en-
hancement of HIV-1 infectivity byCypA–Nef is dependent on its
interaction with the assembling virion and possibly its incor-
poration into virions.
Mutations in the CypA binding site of Gag binding site
diminish both HIV-1 incorporation of CypA–Nef and infectivity
enhancement
Incorporation of cellular CypA into HIV-1 particles is also
dependent on the sequence of specific loop on the surface of the
CA protein (Franke et al., 1994; Gamble et al., 1996; Thali
et al., 1994a). To further test whether HIV-1 incorporation of
CypA–Nef is correlated with infectivity enhancement, we used
two well-characterized HIV-1 Gag mutants, G221A and P222A,
that inhibit CypA binding. Importantly, the ability of Nef toenhance HIV-1 infectivity is unaffected by either of these Gag
mutations (Aiken, 1998). Additional control studies confirmed
that the mutations do not impair the ability of nef-defective
HIV-1 infectivity to be is enhanced by expression of Nef in trans
(Supplementary Fig. 1). The mutant viruses were produced by
cotransfection with the CypA–Nef expression construct, and the
resulting virus particles were assayed for infectivity and ana-
lyzed by immunoblotting to determine the levels of CypA–Nef
incorporation. By contrast to the control virus lacking these
mutations, CypA–Nef enhanced the infectivity of the G221A
and P222A mutant viruses only slightly (Fig. 6A). The levels of
virion-associated CypA–Nef were also decreased in the Gag
mutants despite equivalent cellular expression (Fig. 6B).
To further test the requirement for CypA–Nef binding to Gag
in HIV-1 infectivity enhancement, we analyzed the effects of a
substitution (R55A) in the CypA region of CypA–Nef that
interferes with HIV-1 incorporation of CypA (Dorfman et al.,
1997). This protein, CypA.R55A-Nef, was expressed in cells at
levels similar to wild type CypA–Nef, but its incorporation into
HIV-1 particles was markedly reduced and it failed to enhance
the infectivity of Nef-defective HIV-1 (Supplemental Fig. 2).
Thus, a mutation in the CypA region of CypA–Nef prevented
incorporation of the fusion protein into HIV-1 particles and
suppressed its ability to enhance HIV-1 infectivity. We conclude
Fig. 7. CypA–Nef enhances the infectivity of Nef-defective virions bearing
native HIV-1 Env but not VSV-G. Viral particles were produced by transfecting
293T cells with R7.nef-provirus and Nef or CypA–Nef expression plasmids
in trans (VC, vector control). For HIV-1(VSV-G) pseudotyped particles, the
R7.nef-env-proviral construct was cotransfected with a VSV-G expression
plasmid and the other indicated expression constructs. (A) Analysis of infec-
tivity. Shown are the mean values of triplicate determinations, with error bars
representing one standard deviation. The infectivity of each virus relative to its
respective vector control is shown in panel (B).
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is necessary for infectivity enhancement.
Pseudotyping HIV-1 particles by the vesicular stomatitis
virus glycoprotein (VSV-G) relieves the dependence of HIV-1
infectivity on Nef, probably by rerouting virus entry to an
endocytic pathway (Aiken, 1997; Luo et al., 1998). To determine
whether the enhancing effect of CypA–Nef is also dependent on
the pathway of HIV-1 entry, we produced VSV-G-pseudotyped
HIV-1 particles by cotransfection of Env-defective Nef-
defective proviral constructs with a VSV-G expression vector.
Additional plasmids expressing Nef or CypA–Nef expression
plasmids were also included in the transfections. Assays of the
infectivity of these stocks revealed that the infectivity of the
pseudotyped particles was not significantly altered by Nef or
CypA–Nef expression (Fig. 7). We conclude that infection by
HIV-1(VSV) pseudotyped particles is independent of the
enhancing effect of CypA–Nef as well as Nef. These resultsfurther support the mechanistic similarity of HIV-1 infectivity
enhancement by Nef and CypA–Nef.
Discussion
Despite significant efforts on the part of several laboratories,
the mechanism by which Nef enhances HIV-1 infectivity re-
mains poorly understood. Nef modifies HIV-1 particles in such
a way as to facilitate an early post-penetration step in infection.
One consistently observed Nef-specific virion modification is
incorporation of Nef itself into HIV-1 particles. In this study, we
fused CypA to Nef to allowed controlled incorporation of Nef
into HIV-1 particles via association with Gag during particle
assembly. CypA–Nef specifically enhanced the infectivity of
Nef-defective HIV-1 particles. CypA–Nef was incorporated
into the newly formed viral particles; genetic or pharmacologic
inhibition of the interaction Gag–CypA–Nef interaction re-
sulted in reduced the ability of CypA–Nef to be incorporated
into HIV-1 particles and to enhance virus infectivity. Further-
more, mutations in Nef that inhibit HIV-1 infectivity also
inactivated CypA–Nef, thus demonstrating that the infectivity
enhancement by CypA–Nef mutants is correlated with the
infectivity enhancement by the same Nef mutants. CypA–Nef
was detected in purfied HIV-1 cores, suggesting that the Nef
component determines the subviral localization. Collectively,
these results indicate that CypA–Nef and Nef enhance the
infectivity of Nef-defective virions by a common mechanism.
Our data suggest that interaction of Nef with the assembling
HIV-1 particle is required for infectivity enhancement. Muta-
tions in the CypA segment of CypA–Nef, or in Gag, that
prevented the interaction of the two proteins also inhibited
infectivity enhancement, as did addition of CsA during virus
assembly. It is possible that Nef must be incorporated into HIV-1
particles to enhance infectivity, but our data do not definitively
establish this as Nef may act prior to virus budding and matu-
ration and incorporation into virions may be a by-product of
Nef's accumulation at the site of virus assembly. In a previous
study, Fackler and coworkers reported that the 4E4QNef mutant
enhances HIV-1 infectivity yet is poorly incorporated into HIV-1
particles (Fackler et al., 2006). In attempts to confirm their
observations, we have found that the 4E4Qmutant Nef protein is
readily detectable in pelleted HIV-1 particles rigorously purified
by velocity gradient sedimentation (our unpublished data). In
additional studies, we attributed the discrepancywith the Fackler
data to the antibody used for detection. Therefore, virion incor-
poration of Nef is correlated with infectivity enhancement, and a
role for virion-associated Nef in HIV-1 infection remains a
viable hypothesis.
In this study, we exploited the specific binding of CypA to
Gag to target Nef the assembling virion as a fusion with CypA.
However, the specific mechanism by which Nef itself engages
the virus assembly complex remains unclear. Incorporation of
Nef into HIV-1 particles depends on its membrane-binding
ability, suggesting that Nef may be incorporated into particles
passively by being present at the membrane where the virus
buds. A fraction of cellular Nef protein copurifies with
detergent-resistant membrane domains known as lipid rafts
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and other distinct membrane structures have been implicated in
HIV-1 assembly (Ding et al., 2003; Holm et al., 2003; Ono and
Freed, 2001). It is therefore plausible that Nef localizes to
membranes on which HIV-1 assembly occurs. Additional
evidence suggests that Nef interacts specifically with internal
components of the virion. Nef binds the transframe protein p6⁎
in Gag–Pol, and can interact with both reverse transcriptase
and integrase proteins (Ciuffi et al., 2004). Nef also copurifies
with isolated HIV-1 cores, suggesting that it relocalizes from the
viral membrane to the core during maturation (Kotov et al.,
1999). Uncoating of HIV-1 cores in vitro results in dissociation
of CA and RT, releasing an uncoated ribonucleoprotein com-
plex with which Nef remains associated (Forshey and Aiken,
2003). Thus, while membrane binding is essential for incorpora-
tion of Nef into HIV-1 particles, Nef may perform its function
by specifically targeting an internal component of the HIV-1
core.
How would a Nef-mediated virion modification lead to
enhanced infectivity? Several biochemical virion modifica-
tions have been attributed to Nef, including phosphorylation
of MA (Swingler et al., 1997), stimulation of Env incorpora-
tion (Schiavoni et al., 2004), and elevation of virion-asso-
ciated cholesterol and ganglioside GM1 (Zheng et al., 2003,
2001). Thus, Nef may promote infectivity via multiple effects
on virion composition. Inhibition of proteasome activity en-
hances cellular permissiveness to HIV-1 infection (Schwartz
et al., 1998; Wei et al., 2005), and we recently showed that
addition of proteasome inhibitors during virus inoculation
preferentially enhances the infectivity of Nef-defective par-
ticles, effectively reducing HIV-1 dependence on Nef (Qi and
Aiken, 2007). This finding suggests that Nef-defective virions
are hypersusceptible to proteasomal interference in the target
cell. We hypothesize that a Nef-dependent modification of the
assembling virion renders it less susceptible to proteasome-
dependent restriction in target cells. Despite the attractiveness
of this model, Dueck and coworkers have recently reported
evidence suggesting that the stimulatory effect of proteasome
inhibitors on HIV-1 infection results from an indirect effect on
the cell cycle rather than an antiviral effect of the proteasome
(Dueck and Guatelli, 2007). They were also unable to confirm
our observation that the Nef-defective HIV-1 infection im-
pairment is relieved by proteasome inhibitors (Qi and Aiken,
2007). We suspect that the latter discrepancy is due to differ-
ences in experimental conditions. Though the extent of rescue
of the Nef-defective phenotype by proteasome inhibitors var-
ies between individual experiments, we have consistently ob-
served this effect and we stand by the conclusions of our
previous study. It remains unclear whether the preferential
enhancement of Nef-defective HIV-1 by proteasome inhibitors
is due to elevated susceptibility of Nef-defective HIV-1 to
cytoplasmic degradation or a cell-cycle-dependent selective
block to Nef− particles, and both are possibilities.
Nef may promote proteasomal evasion directly by tethering
the viral core it to a cellular trafficking pathway, thereby faci-
litating intracytoplasmic transport. Nef contains several motifs
that are involved in trafficking in the endocytic pathway, andassociates with known cellular trafficking molecules and path-
ways (reviewed in (Bresnahan et al., 1998; Craig et al., 1998;
Erdtmann et al., 2000; Fackler et al., 2006; Greenberg et al.,
1998; Janvier et al., 2001; Lacaille and Androlewicz, 2000;
Mandic et al., 2001). Thus, Nef could promote association of
the core with components of the endocytic machinery. Several
observations are consistent with this model. First, the impaired
infectivity of Nef-defective HIV-1 particles is relieved by pseu-
dotyping by heterologous viral envelopes which target viral
entry to an endocytic pathway, such as those of vesicular
stomatitis virus and Ebola virus (Aiken, 1997; Chazal et al.,
2001; Luo et al., 1998). This not the case for other heterologous
Env proteins that do not render HIV-1 infection dependent on
endosomal acidification, such as the amphotropic murine
leukemia virus (Aiken and Trono, 1995; Miller et al., 1995).
Thus, endocytic entry of HIV-1 may physically bypass an
intracellular restriction to the Nef-defective viral core. Second,
mutations in a dileucine motif in Nef inhibit both CD4 down-
regulation and infectivity enhancement (Craig et al., 1998),
suggesting that Nef may bind a single cellular factor required
for both of these activities. Finally, the infectivity of Nef-
defective HIV-1 particle is preferentially enhanced by treatment
of target cells with chemicals that depolymerize the cortical
actin cytoskeleton (Campbell et al., 2004), suggesting that
this network forms a barrier to intracytoplamic transport of
Nef-defective HIV-1 cores. Despite the attractiveness of the
model, the evidence in support of a role of Nef in facil-
itating intracellular trafficking of the HIV-1 cores is largely
circumstantial.
The ability of CypA–Nef to enhance HIV-1 infectivity may
facilitate identification of the essential functional regions of
Nef. Nef is composed of two discrete domains, a flexible linker
domain and a globular core domain (Barnham et al., 1997;
Grzesiek et al., 1996; Lee et al., 1996a,b); reviewed in (Geyer
et al., 2001), and thus far it has not been possible to segregate
the membrane-binding function of Nef from infectivity en-
hancement. By targeting Nef to the virion via CypA, it should
be possible to identify the minimal Nef determinants of infec-
tivity enhancement from those necessary for its association with
the assembling virus.
Materials and methods
Cells and viruses
293T and HeLa–CD4/LTR-lacZ (P4) cells were cultured in
Dulbecco's modified Eagle medium (Cellgro) supplemented
with 10% fetal bovine serum, penicillin (50 IU/ml), and strep-
tomycin (50 μg/ml) at 37°C and 5% CO2. The HIV-1 proviral
DNA constructs R7 and R7ΔNef (Aiken and Trono, 1995) were
used for these studies. This viral clone encodes a CXCR4-
dependent HIV-1 envelope protein. The Gag mutants G221A
and P222A have been described (Aiken, 1998). VSV-G-pseudo-
typed HIV-1 particles were produced as previously described
(Aiken, 1997). Viruses encoding amino acid substitutions in
Nef were based on the X4-tropic R9 viral clone and were
previously described (Lundquist et al., 2002). Viruses were
295M. Qi, C. Aiken / Virology 373 (2008) 287–297produced by polyethyleneimine (PEI) transfection of 293T cells
(10 μg of plasmid DNA per 5×106 cells) (Durocher et al.,
2002). Where indicated, CsA (Sandoz, Inc.) was added to a final
concentration of 5 μg/ml 12 h after transfection. One day later, the
culture supernatants were harvested and clarified by passing
through 0.45-μm pore size syringe filters, and aliquots were
frozen at −80°C. The CA contents of the virus stocks were
quantified by p24 enzyme-linked immunosorbent assay (ELISA),
as previously described. The P4 cell line, a HeLa clone engi-
neered to express CD4 and an integrated long terminal repeat
(LTR)-lacZ reporter cassette, was used to quantify HIV-1 infec-
tivity (Charneau et al., 1992). HIV-1 stocks were serially diluted
in culture medium, and samples (0.125ml) were used to inoculate
P4 target cells seeded the day before (20,000 cells per well in
48-well plates). Two hours after inoculation, the cultures were
fed with additional medium (0.5 ml) and cultured for another
48 h prior to being stained with 5-bromo-4-chloro-3-indolyl-β-
D-galactopyranoside (X-gal) to detect infected cells. To deter-
mine the number of infected cells per well, individual wells
were visualized using a charge-coupled device camera equipped
with a macro lens, and blue cells were counted using NIH Image
software. Infections were performed in triplicate, and only val-
ues within the linear range of the infection assay (50–500 blue
cells per well) were used to calculate infectivity. Infectivity was
calculated as the number of blue cells per ng of p24 added to the
well.
Expression plasmids
All expression plasmids in this study were generated in the
CMX-PL1 expression vector. Fusion proteins were produced
by PCR splice overlap extension. The CypA–Nef cDNA was
generated by PCR overlap fusion using the primers 5′-actgtg-
gacaactcgagggtggcaagtggtcaaaaa-3′ (sense) and 5′-tttttgaccact-
tgccaccctcgagttgtccacagt-3′ (antisense). The HA tags and R55A
mutation were also introduced by PCR. The primer for HA-
CypA was: 5′-aaggatccaccatgtacgatgttccagattacgctcttgtcaaccc-
caccgtgttc-3′. The primers for generating the R55A mutation in
CypA were: 5′-tcctgctttcacgcaattatcccggggtttatg-3′ (sense) and
5′-cataaaccccgggataattgcgtgaaagcagga-3′ (antisense). PCR
fragments were inserted into the CMV promoter-based expres-
sion plasmid CMX-PL1 using the BamHI and PstI restriction
sites. The constructs were sequenced to confirm the presence of
the desired open reading frame and the absence of undesired
mutations.
Isolation of HIV-1 cores
Native HIV-1 cores were isolated from concentrated virions
as previously described (Forshey et al., 2002; Kotov et al.,
1999). Fractions containing HIV-1 cores were identified by
quantifying CA by p24 ELISA and by determining the densities
of the gradient fractions by refractometric analysis. Cores pre-
sent in the peak fractions were concentrated by ultracentrifuga-
tion at 100,000×g for 30 min at 4°C following dilution into STE
buffer (10 mM Tris–HCl pH 8.0, 0.1 M NaCl, 1 mM EDTA) to
reduce the solution density.Protein analyses
Cell lysates, viral pellets, and pelleted HIV-1 cores were sub-
jected to electrophoresis on 4–20% polyacrylamide gradient gels
containing SDS (Bio-Rad Laboratories), and proteins were trans-
ferred electrophoretically to nitrocellulose membranes. Protein
blots were probed with antibodies to individual HIV-1 proteins,
including rabbit polyclonal anti-CA and anti-Nef (fromD. Trono),
anti-CypA (Upstate Biotechnology, Inc.), and rat monoclonal to
HA (Roche Applied Science). Following incubation with infrared
dye-conjugated secondary antibodies, protein bands were de-
tected using a LI-COR Odyssey imaging system.
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